Company Insights

YCBD customer relationships

Explore interactive graphBrowse insights index
YCBD customer relationship map

cbdMD (YCBD) — Customer relationships that define the growth driveway

cbdMD operates as a consumer wellness company that develops, manufactures and sells hemp-derived cannabidiol (CBD) products through two primary revenue engines: direct-to-consumer e-commerce and wholesale distribution into retail and beverage channels. The company monetizes through product sales, channel partnerships with regional distributors and selective commercial agreements (including a recently disclosed commission-based consulting arrangement). For investors, the proof points to watch are sell-through at retail, distributor rollouts in new states and the economics of partnership agreements that can drive incremental revenue without heavy capex.
Discover a systematic view of partner exposure at https://nullexposure.com/.

How cbdMD actually sells: a compact operating model

cbdMD’s revenue mix is split between online consumer sales and wholesale relationships with distributors and retailers. Payment terms are typically short — standard net-30 commercial terms are in place when control transfers to the customer — and the company’s distribution approach combines national e-commerce reach with regional beverage and retail rollouts. This creates a business model that is sales‑driven, channel-dependent and inventory‑sensitive: cash conversion and distributor sell‑through directly influence reported revenue and working capital.

Key company-level signals:

  • Contracting posture: Short-term payment terms (typically 30 days) imply tight working-capital cycles and limited long-term contractual revenue visibility.
  • Counterparty mix: Sales are to both individual consumers (e-commerce) and wholesale partners (distributors/retailers), creating a diversified sales book but also exposure to retail shelf placement dynamics.
  • Geographic footprint: Active expansion in North America with regulatory efforts for EMEA and growth initiatives in LATAM; international approvals and Novel Foods filings signal an intention to expand beyond the U.S. market.
  • Role and materiality: The company operates as both seller and supplier to distributors; some distribution agreements include termination provisions and potentially material fees tied to sell‑through, elevating counterparty importance in revenue realization.
  • Product focus: Core product orientation remains consumer wellness supplements powered by natural compounds, with beverage placements forming a strategic growth vector.

Partner map — the relationships that move revenue

Majik Medicine, LLC

cbdMD executed a five‑year consulting agreement with Majik that includes a 15% commission on increased sales from licensed practitioners, giving the company a structured revenue share on practitioner-driven growth (FY2025 10‑K filing). This is a targeted monetization vehicle aimed at practitioner channels and a signal the company is layering commissionable, performance-linked arrangements into its commercial mix (10‑K, FY2025).

Best Brands

Best Brands is a regional distribution partner used in cbdMD’s Southeast expansion, with a Tennessee rollout noted in the company’s public coverage. The company announced this expansion Sept. 16, 2025, reflecting incremental distribution placements across the region (TechS2 report referencing Sep. 16, 2025).

Bevtalk Distribution

Bevtalk Distribution is the vehicle for Herbal Oasis beverage distribution in Florida, intended to scale placements across convenience stores, independent retailers and specialty beverage accounts; the partnership announcement was published Oct. 9, 2025 (TechS2 and company news coverage, Oct. 9, 2025). This relationship moves cbdMD further into on‑premise and retail beverage channels where velocity matters.

Bevtalk (as reported in corporate news)

Corporate news referencing cbdMD’s investor events and conference calls highlights Herbal Oasis’s Florida footprint expansion via Bevtalk; the item was circulated in fiscal‑year commentary around the company’s FY2026 reporting (Finviz news, FY2026 coverage). This underscores the marketplace narrative that beverage distribution is a strategic growth lever.

Morales Beverage Group

Morales Beverage Group is the named distributor for cbdMD’s Herbal Oasis expansion into Louisiana following momentum in Texas, representing the company’s state‑by‑state rollup strategy for beverage products (Finviz news, FY2026). This reflects a replication strategy—if placements in one state deliver sell‑through, cbdMD layers in additional regional beverage distributors.

Bluebird Botanicals

Bluebird Botanicals shows up in investor call coverage as an acquired or added brand that contributes incremental revenue and a loyal customer base, helping broaden cbdMD’s wellness portfolio beyond single-brand dependence (earnings call transcript, Q1 FY2026, InsiderMonkey). This addition diversifies product offerings and customer cohorts through established loyalty.

(Each of the relationships above is represented in company filings or public news coverage cited by fiscal period.)

Explore a complete mapping of these commercial linkages at https://nullexposure.com/.

What these relationships imply for investors

The partnership portfolio demonstrates an active commercial strategy focused on distribution expansion and brand layering rather than capital‑intensive growth. Two themes define risk and opportunity:

  • Growth leverage via distribution: Regional beverage distributors (Bevtalk, Morales) and retail partners (Best Brands) can deliver rapid shelf expansion and scaled revenue with limited capex, but revenue realization depends on retailer sell‑through and inventory turns.
  • Contract economics and short-term exposure: Short payment terms and commission arrangements (Majik’s 15% commission) concentrate near-term cash flow sensitivity and elevate the importance of execution at point-of-sale. The company’s small market capitalization (approximately $6.6M) and negative operating margin amplify the impact of any distributor underperformance.

Financial context: cbdMD reported roughly $19.0M revenue TTM and a gross profit of about $11.6M, but operating margins remain negative; the business relies on commercial momentum and faster sell‑through to convert distribution rollouts into profitable scale.

Risks that investors should underwrite

  • Distributor concentration and termination economics: Several agreements include termination clauses and potential fees that could be material relative to sell‑through, which concentrates execution risk on a handful of regional partners.
  • Execution on new channels: Beverage rollouts require different trade execution and merchandising than supplements; underperformance in convenience or beverage accounts reduces the expected uplift.
  • Regulatory and geographic rollout: EMEA Novel Foods filings and LATAM sanitary registrations are progress signals, but international commercialization timelines will influence medium‑term growth.

Read deeper operational coverage and partner impact analysis at https://nullexposure.com/.

Bottom line: where value comes from

cbdMD’s strategy is to monetize expanded distribution and brand acquisitions while keeping capital intensity low. Value creation depends on converting distributor placements into repeatable sell‑through, and on embedding new brands into loyal customer cohorts. For investors, monitor retail velocity metrics, state‑level beverage rollouts and any updates to commission or termination provisions that affect revenue recognition. The partnership set — Majik, Best Brands, Bevtalk/Bevtalk Distribution, Morales Beverage Group and Bluebird Botanicals — forms the tactical backbone of that strategy; each is a near‑term lever on top‑line growth and cash flow.

If you evaluate counterparty exposure or need a consolidated partner-risk scorecard for due diligence, start here: https://nullexposure.com/.